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Cellular TRIM33 restrains HIV-1 infection
by targeting viral integrase for proteasomal
degradation
Hashim Ali1,2, Miguel Mano 1,6, Luca Braga1,2, Asma Naseem3, Bruna Marini1,7, Diem My Vu1, Chiara Collesi1,4,
Germana Meroni5, Marina Lusic1,8 & Mauro Giacca 1,2,4
Productive HIV-1 replication requires viral integrase (IN), which catalyzes integration of the
viral genome into the host cell DNA. IN, however, is short lived and is rapidly degraded by
the host ubiquitin-proteasome system. To identify the cellular factors responsible for HIV-1
IN degradation, we performed a targeted RNAi screen using a library of siRNAs against all
components of the ubiquitin-conjugation machinery using high-content microscopy. Here
we report that the E3 RING ligase TRIM33 is a major determinant of HIV-1 IN stability. CD4-
positive cells with TRIM33 knock down show increased HIV-1 replication and proviral DNA
formation, while those overexpressing the factor display opposite effects. Knock down of
TRIM33 reverts the phenotype of an HIV-1 molecular clone carrying substitution of IN
serine 57 to alanine, a mutation known to impair viral DNA integration. Thus, TRIM33 acts as
a cellular factor restricting HIV-1 infection by preventing provirus formation.
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Integration into the host cell genome, which is catalyzed bythe virus-encoded integrase (IN) enzyme, is a hallmark ofall members of the Retroviridae family1,2. In both lenti- and
gamma- retroviruses, functionally active IN is a product of endo-
proteolytic cleavage of the Gag-Pol polyprotein by action of
the virally encoded protease. As a result of this process, in
the case of HIV-1, mature IN harbors an N-terminal phenylala-
nine, which renders the protein susceptible to rapid degradation
by the 26S proteasome following recognition by the class of
E3 ubiquitin ligases known as recognins (N-end rule ubiquitin
E3 ligases), which recognize N-degron signals3,4. When the
first amino-acid of HIV-1 IN is mutated to methionine, IN
stability increases, however the protein is still short-lived4–8, an
indication that IN is targeted for degradation through the pro-
teasomal pathway also independent from N-terminal recognition.
Indeed, this conclusion is consistent with the long-standing
observation that inhibition of the proteasome enhances HIV-1
infection9,10.
The 160-kDa HIV-1 Gag-Pol polyprotein is packaged into
virions preceding proteolytic processing, which occurs in the
virions after budding. Upon target cell infection, mature IN (32
kDa) is part of the viral pre-integration complex (PIC), which
provides a secluded environment where reverse transcription
of viral RNA into blunt-ended, linear DNA takes place11. Part
of the PIC is then transported into the nucleus, where viral IN
eventually exerts its enzymatic function. Here, the protein enters
in contact with various nuclear proteins, including factors that
increase its efficacy and protect it against proteasomal degrada-
tion. These include the transcriptional coactivator lens
epithelium-derived growth factor/transcription coactivator p75
(LEDGF/p75)5,12,13 and Ku70, a component of the cellular
double-stranded DNA break repair through the non-homologous
end-joining pathway14. For both factors, binding to IN was
shown to prevent its proteasomal degradation7,14.
In addition, our previous work has shown that IN stability,
and thus enzymatic function, is increased by post-translational
modification. Phosphorylation of serine 57 (S57) in the IN
catalytic core by cellular c-Jun N-terminal kinase (JNK) renders
the protein a substrate for cis/trans isomerization by the peptidyl-
prolyl isomerase Pin1; this induced structural modification
markedly increases IN half-life by reducing its ubiquitination
and is required for efficient HIV-1 infection15. A point mutation
in IN(S57) leads to accelerated IN degradation and severely
restricts infectivity of the virus. Consistent with the stabilizing
role of JNK-induced IN(S57) phosphorylation, lack of JNK
expression restricts viral infection in resting, primary CD4+ T
lymphocytes15.
Taken together, these studies indicate that, in the infected
cells, IN is a substrate for degradation by the ubiquitin-
proteasomal pathway. This pathway consists in the sequential
action of three different classes of enzymes. The 76 aa-
polypeptide ubiquitin is first activated by binding to one of a
few E1 ubiquitin-activating enzymes, to be then transferred
to one of ~40 E2 conjugation enzymes, which act in conjunction
with over 600 E3 ubiquitin protein ligases, which provide
target specificity by recognizing the proteins to be tagged and
eventually transferring ubiquitin to them16–19. The poly-
ubiquitinated substrate proteins are then recognized by the 26S
proteasome machinery and degraded into short peptides20. E3
ligases are classified into two main classes (RING and HECT)
based on conserved structural domains and the molecular
mechanism of ubiquitin transfer to the substrate. The RING
(really interesting new gene)-type E3 ligases catalyze direct
transfer of ubiquitin from the ubiquitin-loaded E2 enzyme to
the substrate, concurrently binding with the cognate E2 and
the substrate17,21. In contrast, the HECT (homology to E6AP
C-terminus)-type E3 ligases require two steps to transfer ubi-
quitin to the substrate, with ubiquitin being first transferred
from the E2 to an active site cysteine in the E3 and then from
the E3 to the substrate22,23.
As a consequence of this mechanism, it can be predicted that,
in HIV-1 susceptible cells, one or more cellular E3 ligases must
exist, in addition to those involved in N-terminal recognition,
which target IN for degradation through the ubiquitin-
proteasome pathway, thus hampering HIV-1 infection by
impairing viral cDNA integration. The identity of these E3 liga-
ses, however, has escaped identification so far.
Here we report the results of a high-throughput screening
(HTS) using a library of siRNAs against the whole set of com-
ponents of the ubiquitin-conjugation machinery, including E1
and E2 enzymes and E3 RING and HECT ligases (598 target
genes) using high-content microscopy, in search for factors that
drive IN ubiquitination and degradation. We report that the
cellular E3 RING ligase TRIM33 is a major determinant of HIV-1
IN stability inside the cells binding the IN carboxy-terminal
domain through its RING portion and determining its poly-
ubiquitination. Lack of TRIM33 overcomes the effect of Pin1
knock-down and rescues infectivity of an HIV-1 mutant carrying
the destabilizing IN (S57) mutation. Thus, TRIM33 acts as
an inhibitory factor hampering HIV-1 infection by decreasing
IN function and thus preventing viral cDNA integration into
the host cell genome.
Results
Cellular ubiquitin-proteasome targets HIV-1 IN for degrada-
tion. We examined HIV-1 IN protein stability in HeLa cells upon
transfection of a plasmid expressing Flag-tagged IN15 in the
presence or absence of the proteasome inhibitor MG132 in cells
treated with cycloheximide (CHX, 30 μg/ml), which blocks de
novo protein synthesis. The levels of IN progressively diminished
over time, with an estimated half-life of ~60 min, in line with
our previous results15; proteasome inhibition maintained high
protein levels over time (Fig. 1a for experimental scheme, Fig. 1b
representative immunoblot and Fig. 1c for quantification of
three independent experiments). The levels of EGFP expressed
from a separate plasmid transfected together with IN in the
same cells were unaffected by the treatments and remained stable
over time (Fig. 1b). In similar experiments, the half-life of IN
from the Moloney-Murine Leukemia Virus (MLV) gammare-
trovirus was > 5 h and its sensitivity to proteasomal degradation
was minimal (Fig. 1e, f). Collectively, these results indicate that
HIV-1 IN, when expressed inside the cells, is subject to relatively
rapid proteasome-mediated degradation.
We asked whether silencing of some of the established
interacting partners of HIV-1 IN might affect its levels. We
found that siRNAs against LEDGF/p75, Ku70, Pin1, and
the combination of JNK1 and JNK2 significantly reduced the
amount of IN (Fig. 1g–i for experimental scheme, representative
immunoblot, and quantification, respectively). We also knocked
down the VBP1 protein, which was reported to tether IN to the
von Hippel Lindau (VHL)/Cullin 2 (CUL2) ubiquitin degradation
complex, and VHL and CUL2 themselves; in none of these cases,
however, IN levels were increased. For all these knock-downs,
immunoblotting analysis revealed >65% downregulation of the
respective siRNA targets (Supplementary Fig. 1). None of the
siRNAs had an effect on the levels of the EGFP protein expressed
in the same cells in a separate experiment (Fig. 1h).
Collectively, these results indicate that the host ubiquitin-
proteasome system targets HIV-1 IN for degradation through a
still unrecognized ubiquitin ligase. They also show that a few
cellular factors protect IN from degradation.
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High throughput screening for cellular factors responsible for
HIV-1 IN levels. To identify host factors responsible for IN
degradation, we performed a high-content, fluorescence micro-
scopy-based, high throughput screening (HTS) using a library of
siRNAs against factors in the ubiquitin-conjugation system,
including E1 and E2 enzymes and E3 RING and HECT domain
ligases (598 target genes, 4 siRNAs per target, pooled). HeLa cells
were reverse-transfected in 96-well plates with each siRNA pool
(efficiency of transfection >85%), in duplicate, and 24 h later were
transfected with EGFP-IN. After further 48 h, the cells were fixed,
nuclei were counterstained with Hoechst 33342 and GFP fluor-
escence was analyzed by high-content microscopy (workflow
shown in Fig. 2a; 2500 cells in the duplicates were analyzed
per experimental condition). The EGFP-moiety did not interfere
with IN degradation, since the fusion protein responded to
proteasome inhibition in a dose-responsive manner similar to
the wild-type IN (Supplementary Fig. 2a, b). In cells expressing
the protein and treated with CHX and MG132, the levels of
EGFP-IN progressively decreased over time, with an estimated
half-life of ~60 min (Supplementary Fig. 2c, d, similar to Flag-
tagged IN. Cell viability in the screening was assessed by counting
nuclei number; after assessing normal distribution (Shapiro-Wilk
test), siRNAs exerting a toxic effect Zscore P ≤ 0.10) were exclu-
ded from further analysis.
Two independent replicates of the screening were conducted;
the replicates showed good reproducibility (Spearman r= 0.74;
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Fig. 1 Degradation of retroviral integrases by the host ubiquitin-proteasome system. a Schematic representation of the HIV-1 IN stability assay. HeLa cells
were cotransfected with plasmids expressing Flag-tagged IN or EGFP; 48 h later, cells were treated with cycloheximide (CHX) in the presence and absence
of the proteasome inhibitor MG132. bMeasurement of HIV-1 IN stability. Flag-IN-expressing HeLa cells were treated with CHX (30 μg/ml) with or without
MG132, followed by protein detection at different time points using an anti-Flag antibody. Tubulin levels served as a loading control and EGFP levels as a
transfection and specificity control. c Quantification of HIV-1 IN protein levels in the presence and absence of MG132 in CHX-treated cells at the indicated
time points. Data are mean ± SEM; n= 3 independent experiments. d Schematic representation of the MLV IN stability assay. e Measurement of MLV- IN
stability. Experiments were performed as in panel c. f Quantification of MLV-IN protein levels. Data are mean ± SEM; n= 3 independent experiments.
g Knock-down of cellular factors to assess HIV-1 IN levels. HeLa cells were transfected with a plasmid expressing pFlag-IN and either transfected 24 h in
advance with siRNAs against selected cellular factors or treated, 48 h later, with MG132. h Representative experiment showing the levels of HIV-1 IN after
knock-down of selected cellular factors by RNAi, as indicated. Cell treatment with MG132 served as a positive control. IN levels were analyzed in whole cell
lysates by immunoblotting with anti-Flag antibody. Immunoblotting for Tubulin served as a loading control. The bottom panel shows a western blotting for
EGFP in a representative experiment to show lack of effect of any of the tested siRNAs on EGFP levels. i Quantification of HIV-1 IN levels in whole cell
extracts of cells in which the indicated factors were knocked down by siRNA transfection. Data are normalized for Tubulin levels and expressed as fold over
cell treatment with non-targeting NT2 siRNA control. Data are mean ± SEM; n= 3 independent experiments; *P < 0.05; **P < 0.01; one-way ANOVA
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Fig. 2b). Results of the two screening for the 557 siRNAs not
impairing cell viability, expressed as log10-fold over mock
control, are reported in Supplementary Table 1. Cell treatment
with MG132 and with a non-targeting (NT) siRNA (both
performed in quadruplicate) served as internal controls.
These replicate screenings identified 35 siRNAs that increased
the percentage of EGFP fluorescent cells more than twofold than
control. We focused our attention on the 6 genes the knock-down
of which was among the top 10 most effective in both screenings
(in red in Fig. 2b and Supplementary Table 1) and on the
4 additional genes the knock down of which was among the
top 10 in one of screening while anyhow showing an effect ≥2
fold over control in the other screening (in green in Fig. 2b and
Supplementary Table 1).
These included the E2 protein UBE2J2 (Ubc6), an ER-
associated E2 conjugating enzyme involved in the degradation
of misfolded cellular proteins24,25 and nine E3 ubiquitin ligases.
Two of these were F-box proteins, which form functional
complexes with SKP1 and CUL to generate multisubunit E3
ligases (SCF)26: FBXO42 and FBXO28, the latter known to be an
important regulator of cell cycle progression27,28. Other E3 ligases
were RFPL3, shown to increase HIV-1 integration by modulating
the activity of the HIV-1 PICs29; RNF31 (also known as HOIP), a
component of the linear ubiquitin chain assembly complex
(LUBAC), an E3 ligase that generates linear poly-ubiquitin
chains30; DTX2, a member of deltex protein family, acting as a
positive regulator of Notch signaling31,32; NHLRC1/Malin,
essential for the ubiquitin-mediated degradation of Laforin33,
mutations of which lead to Lafora disease34,35; RNF125 (also
known as TRAC-1, which positively regulates T-cell activation36 -
this protein is known to downregulate HIV-1replication at
the transcriptional level in a ubiquitin–proteasome dependent
manner37 and is a component of the innate immune response38–;
and, finally, two members of the TRIM family, which harbors
antiviral activities against RNA and DNA viruses39,40, TRIM72
(also known as mitsugumin-53, MG53), a skeletal and cardiac
tissue-specific protein involved in the plasma membrane repair41
and TRIM33, alias TIF1γ/RFG7/PTC7/Ectodermin, which
belongs to the Transcriptional Intermediary Factor1 (TIF1)
subfamily of TRIM proteins42 and has variously been implicated
in tumorigenesis43.
We wanted to ensure specificity of the HTS results for these top
10 hits. First, we tested the effects of each of the siRNA pools by
immunoblotting lysates of siRNA-treated cells with antibodies
against the respective proteins. The levels of 6 of the investigated
proteins (TRIM33, FBOX28, RNF31, RNF125, RFPL3, and
DTX2) were effectively decreased after siRNA treatment (>85%
decrease; Fig. 2c), while none of the commercially available
a b c
siRNAs:
MG132:
pFlagIN:
pEGFP:
- β-Catenin
- Tubulin
- HIV INWB: Flag
WB: β-catenin
WB: Tubulin
–
+
+
+
–
–
–
+
M
oc
k
+
–
+
+
F
B
O
X
28
+
–
+
+
F
F
O
X
42
+
–
+
+
P
in
1
+
–
+
+
T
R
IM
33
+
–
+
+
T
R
IM
72
+
–
+
+
R
N
F
31
+
–
+
+
R
N
F
12
5
+
–
+
+
R
F
P
L3
+
–
+
+
D
T
X
2
+
–
+
+
N
H
LR
C
1
+
–
+
+
U
B
E
2J
2
+
–
+
+
N
T
1
siNT1:
siRNAs:
+
–
–
+
+
–
–
+
FBOX28
HSC70
RNF31
HSC70
TRIM33
HSC70
RNF125
HSC70
RFPL3
HSC70
HSC70
DTX2
d
e
f
EGFP-IN Hoechst Merge
si
N
T
1
M
G
13
2
si
P
in
1
si
T
R
IM
33
si
F
B
O
X
28
si
D
T
X
2
si
U
B
E
2J
2
Ubiquitin-conjugation siRNA 
library on 96-well plates
(~600 human genes)
EGFP-IN transfection
Fixation and 
nuclei staining
0 h
24 h
72 h
siRNA reverse transfection
GFP expression
analysis
0
4
5
6
3
1
si
N
T
1
M
G
13
2
si
P
IN
1
si
R
N
F
31
si
F
B
O
X
42
si
D
T
X
2
si
R
N
F
12
5
si
U
B
E
2J
2
si
R
F
P
L3
si
N
H
LR
C
1
si
F
B
O
X
28
si
T
R
IM
72
H
IV
 IN
/T
ub
ul
in
(f
ol
d 
ov
er
 N
T
1)
si
T
R
IM
33
2
Top hits
**
*
**
**
–2.0 –1.0 1.0
–2.0
2x over Control
–1.0
1.0
2x
 o
ve
r c
on
tro
l
Fold GFP+ cells (log10 R1)
F
ol
d 
G
F
P
+
 c
el
ls
 lo
g1
0 
R
2)
UBE2J2
MG132 RFPL3
FBXO28
RNF31
TRIM33
TRIM72
NHLRC1
RNF125
DTX2
FBXO42
- EGFPWB: GFP
Fig. 2 High-throughput, siRNA-based screening to identify cellular factors regulating HIV-1 integrase stability. a Workflow for the siRNA-based screening.
Cellular fluorescence, as surrogate of IN levels, was analyzed by automated, high-content fluorescent microscopy. b Results of screening. The graphs show
the log10 values of the fold change of EGFP-positive cells over control in the two replicate screenings (R1 and R2). The dotted lines show 2x increase over
Control (pool of results using 4 non-targeting siRNAs and mock-transfected cells). The 6 siRNAs in red are those that were in the top 10 in both
screenings. The 4 siRNAs in green are those that were among the top 10 in one of screening while anyhow showing an effect ≥2 fold over control in the
other screening. The effect of MG132 is shown in blue. c Confirmation of effective silencing of Pin1, TRIM33, FBOX28, RNF31, RNF125, RFPl3, and DTX by
immunoblotting with the respective antibodies. Cells transfection of non-targeting siRNA1 (siNT1) was used as a control. HSC70 served as a loading
control. d Representative immunoblot showing the levels of HIV-IN after knock-down of the top 10 E3 ligases from the screening. HeLa cells were
transfected with siRNAs against the identified factors or with a siRNA against Pin1, followed by transfection of Flag-IN and EGFP. Forty-eight hour later the
levels of IN were assessed by anti-Flag immunoblotting. Tubulin served as a loading control; β-catenin was used to confirm effect of the MG132 treatment.
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antibodies we could test were active against TRIM72, FBOX42,
NHLRC1, and UBE2J2. Second, we tested the top 10 siRNA pools
to ensure that they effectively upregulated the levels of IN by
immunobloting of cell lysates expressing IN-Flag. We found that
four siRNAs (against TRIM33, FBOX28, DTX2, and UBE2J2)
increased IN protein levels significantly; β-catenin, which is
actively degraded by the ubiquitin proteasome pathway44, served
as an endogenous control in these experiments (representative
blot in Fig. 2d and quantification in Fig. 2e). The effect of these
four siRNA pools in cells expressing EGFP-IN is shown in Fig. 2f.
Those against TRIM33, FBOX28, and DTX2 were specific for IN,
since they did not affect the levels of EGFP alone transfected
together with IN (separate experiment at the bottom Fig. 2d). Of
interest, treatment with the same siRNA pools also upregulated
IN levels in cells in which Pin1 had been downregulated, thus
determining IN instability15 (Supplementary Fig. 2e, f for a
representative immunoblot and quantification, respectively). In
particular, the knock-down of TRIM33 in Pin1-depleted cells
restored IN at levels comparable to those determined by MG132,
consistent with the conclusion that IN instability induced by Pin1
knockdown is mediated by TRIM33-mediated IN degradation.
Third, we deconvoluted the four siRNA pools against TRIM33,
FBOX28, DTX2, and UBE2J2 by individually testing the effect, on
the respective protein level and on IN stability, of the four
individual siRNAs composing each of these pools. Three out of
four siRNAs against TRIM33 decreased the levels of this protein
and, at the same time, increased those of IN (Supplementary
Fig. 2g). In the cases of the FBOX28, DTX2, and UBE2J2 siRNAs,
instead, there was inconsistency between the extent of the
respective protein knock-down and the increase in IN levels
(Supplementary Fig. 2h–j). Considering these findings, and after
having observed the marked increase in IN levels after TRIM33
knock-down, we decided to concentrate our attention on this
protein in the subsequent experiments.
TRIM33 is the only TIF1 family member that regulates HIV-1
integrase stability. The TIF1 subfamily of TRIM proteins con-
tains four members: TRIM24, TRIM28, TRIM33, and TRIM66.
The first three TIF1 proteins are highly conserved in domain
organization and amino acid sequence (Fig. 3a) and were
shown to form complexes in hepatocellular carcinoma cells45,46.
Therefore, we asked whether other TRIM33 family members
also affected IN stability. We silenced TRIM24 and TRIM28
using both siRNA pools and individual siRNAs against the two
proteins – obtained after pool deconvolution –, in cells expressing
HIV-1 IN. In neither case we observed increased IN levels despite
effective protein knock-down; cell treatment with MG132 served
as a control for these experiments (Fig. 3b, c for TRIM24 and
TRIM28, respectively). An increase in IN levels was only observed
in cells transfected with siRNA #23 against TRIM24, which we
attribute to an off-target, unspecific effect. In these experiments,
we also checked whether the specific knockdown of TRIM24 or
TRIM28 affected the reciprocal protein levels, as well the levels of
TRIM33. In no case the individual protein knock-down altered
the amounts of the other TIF1 members. Similarly, knock-down
of TRIM33 had no effect on the levels of either TRIM24 or
TRIM28, while it markedly increased IN amount, thus confirm-
ing the previous findings (Fig. 3d). We conclude that TRIM33
is the only TIF1 protein regulating HIV-1 IN levels.
Next we assessed whether TRIM33 silencing stabilized HIV-1
IN after blocking protein synthesis with cycloheximide. In these
experiments, we transiently knocked-down TRIM33, Pin1, or
LEDGF/p75 24 h before cell transfection with Flag-IN. After
additional 48 h, we treated cells with cycloheximide for 0, 30, 60,
and 90 min IN stability was examined by immunoblotting with
anti-Flag antibody. In TRIM33-depleted cells, the basal levels of
IN were increased and its rate of disappearance markedly slowed
down, indicative of protein stabilization (~75% of protein still
present after 90 min of CHX treatment vs. <20% in control cells;
Fig. 3e for representative blots and Fig. 3f for quantification).
Depletion of LEDGF/p75 showed an opposite effect, albeit more
modest, consistent with the protective function of this factors on
IN degradation. The results of these experiments indicate that
TRIM33 is a major determinant of IN stability.
Next we wondered whether TRIM33 was capable to also
modulate the stability of MLV IN or exclusively acted on the
HIV-1 protein; in this set of experiments we also analyzed the
effect of other HIV-IN-stabilizing cellular factors (Pin1, LEDGF/
p75, and Ku70) on MLV IN. Cells were transfected with siRNAs
against the individual factors under investigation together with
plasmids expressing either Flag-tagged HIV-1 or MLV IN
proteins. Forty-eight hours post transfection, total IN levels were
examined by immunoblotting with anti-Flag antibody. HIV-1 IN
levels increased upon TRIM33 silencing and decreased upon
silencing of the stabilizing factors (Fig. 3g top panel for a
representative immunoblot and Fig. 3h for quantification). In the
case of MLV IN, neither knock-down of TRIM33 increased nor
silencing of LEDGF/p75 or Ku70 decreased protein level, while
Pin1 knock-down even augmented it (Fig. 3g bottom panel and
Fig. 3h).
The HIV-1 IN protein, which normally carries an N-terminal
phenylalanine, is a target of the proteasome-dependent N-rule
protein degradation pathway3. To assess whether TRIM33 might
be involved in this process, we expressed untagged IN by
transfecting HeLa cells with bicistronic plasmids co-expressing
EGFP and various IN variants carrying different N-terminal
amino acids3 (Supplementary Fig. 3a). As expected, the levels of
variants carrying phenylanine or histidine as the first amino acid
were markedly reduced by proteasomal degradation, as evidenced
by the capacity of MG132 to rescue this phenotype (Supplemen-
tary Fig. 3b). Depletion of TRIM33 increased the levels of all
variants, but did not revert the effect of the N-terminal rule
pathway on the phenylanine and histidine-carrying IN proteins.
These results indicate that TRIM33 affects IN stability with a
mechanism that is additional to that of the N-terminal rule, also
consistent with binding of TRIM to a portion of IN different from
the N-terminal domain (cf. later).
TRIM33 E3 ligase marks IN for degradation via poly-
ubiquitination. TRIM33 belongs to the RING type ubiquitin
E3 ligase family, the members of which ubiquitinate substrate
proteins by directly binding17,47. The protein has a predominately
nuclear localization, both soluble and chromatin-bound, however
a significant portion of it was is detected in the cytoplasm
(Supplementary Fig. 4). Recent information indicates that cyto-
plasmic TRIM33 is also present in CD4+ T lymphocytes48; here,
the protein can interact with incoming HIV-1 IN. Thus, we
wanted to further explore the interaction between TRIM33 and
IN by co-immunoprecipitation studies. A Flag-IN expressing
plasmid, or control plasmids expressing Flag-Luciferase or Wer-
ner helicase interacting protein1 (WHIP1) were transfected into
HEK293T cells. WHIP1 contains a zinc-finger domain and is
found in both nucleus and cytoplasm. Similar to TRIM33,
WHIP1 also binds chromatin49,50. The Flag-tagged proteins were
immunoprecipitated with anti-Flag M2 magnetic beads and the
amount of endogenous TRIM33 in the precipitated immuno-
complexes was examined by western blotting with an anti-
TRIM33 antibody (Fig. 4a). We found that endogenous TRIM33
bound IN; both transfected proteins and endogenous TRIM33
were well expressed inside the cells.
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To map the domain of IN that mediates binding to TRIM33,
we performed pull-down assays using GST-tagged proteins
corresponding to full-length IN or segments of the protein
corresponding to its N-terminal domain (NTD), catalytic core
domain (CCD) and C-terminal domain (CTD); GST alone served
as a negative control (Fig. 4b). Binding of these proteins to
in vitro translated, [35S]-labeled TRIM33 revealed binding to full
length IN and to the IN CTD domain (>8.5% binding; P < 0.01 in
both cases), but not to the other domains of the protein (<3%
binding; Fig. 4c). All the GST fusion proteins were expressed and
purified at comparable levels for the GST-pull down binding
assays (Coomassie blue-stained gel at the bottom of Fig. 4c).
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Next we examined IN ubiquitination in HEK293T cells
transfected with Flag-tagged IN together with a plasmid
expressing HA-tagged ubiquitin, followed by analysis of the IN
ubiquitination profile in samples immunoprecipitated with Flag
M2 beads. We found that ubiquitin molecules are mainly linked
to IN through lysine 48 (K48), rather than K63, consistent with
the notion that K48-polyubiquitinated IN is further recognized by
the cellular ubiquitin/proteasome system for protein degradation
(Fig. 4d). These results were further validated by co-expressing
various HA-tagged ubiquitin mutants (K48, K48R, and KO/no
lysine) together with Flag-tagged IN in HEK293T cells, followed
by IN immunoprecipitation and visualization of its modification
using HA and anti-K48 antibodies. Here again we found
increased levels of ubiquitinated IN in cells overexpressing K48-
ubiquitin compared to those transfected with a K48R or KO-no
lysine ubiquitin mutants (Supplementary Fig. 5a). These results
are all consistent with the conclusion that K48-linked poly-
ubiquitination mainly leads to HIV-1 IN degradation.
Next, we examined polyubiquitination of IN in TRIM33-
depleted cells, as well as in Ku70-depleted cells, in the absence
of proteasome inhibitor. We found that the knockdown of
TRIM33 reduced IN polyubiquitination (Fig. 4e, f). Of note, in
these experiments the knockdown of TRIM33 also determined
a significant accumulation of non-polyubiquitinated protein, in
line with its stabilizing effect on the protein.
We also assessed the involvement of different E2 conjugating
enzymes in IN poly-ubiquitination. These experiments were
performed using purified recombinant Flag-tagged TRIM33
(obtained in mammalian cells; Supplementary Fig. 5b) and
recombinant GST-IN (obtained in E. coli, Supplementary Fig. 5c),
using an E2 scan kit analyzing the effect of 34 different E2 ligases.
We found that multiple E2s are capable of TRIM33-dependent
IN ubiquitination, including 2E1, 2E2, 2E3, 2F, 2G1, 2H, and 2Q
(Supplementary Fig. 5d).
Mapping the TRIM determinants involved in IN regulation. To
identify which TRIM33 domain is important for its interaction
with IN, we co-expressed EGFP-tagged IN together with various
Flag-tagged TRIM33 variants carrying deletions in the PHD/
Bromodomain, RBCC/TRIM domain or both (ΔPHD/Bromo,
ΔTRIM and Linker respectively; Supplementary Fig. 6a). After
a
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recovery of the TRIM33 proteins using anti-Flag M2 magnetic
beads, we tested the immunoprecipitates for the presence of
IN. We found that IN bound to wild-type TRIM33 and the
ΔPHD/Bromo deletant, but not to the other mutants (Supple-
mentary Fig. 6b). All the proteins were equally expressed in the
cells. We conclude that integrity of the RBCC/TRIM domain at
the N-terminus of TRIM33 is essential for its interaction with IN.
TRIM33 harbors two catalytically active domains, RING
and PHD, which can post-translationally modify the target
proteins by conjugating them with ubiquitin and ubiquitin-like
molecules16,17,51. To understand which of these two domains
is responsible for IN ubiquitin-mediated degradation, we co-
expressed EGFP-IN and HA-Ubiquitin with Flag-tagged wild-
type TRIM33 or two catalytically inactive mutants bearing
amino acid substitution in either of these domains, namely
RING(C125A/C128A) and PHD(C901A/C902A/C905A); Fig. 5a.
Forty-eight hours later, cells were treated with MG132 for 5 h.
Then IN was immunoprecipitated from cell lysates with an anti-
GFP antibody and the ubiquitinated forms of the proteins were
visualized by immunoblotting with an anti-HA antibody (Fig. 5b
for a representative immunoblot and Fig. 5c for quantification).
Wild-type TRIM33 increased IN poly-ubiquitination, an effect
that was abolished by the RING domain point mutations;
mutations in the PHD domain, instead, had no apparent effect.
Both TRIM33 mutants, however, were equally effective as the
wild-type protein in binding to IN in GST pull-down assays
(Supplementary Fig. 6c).
We also examined HIV-1 IN protein stability in HeLa cells
stably transfected to express an shRNA against TRIM33 (TRIM33
KD), the wild-type TRIM33 protein or the catalytically inactive
RING(CA) mutant. Analysis of protein levels was performed at
different times after treatment with cycloheximide. We found that
stable depletion of TRIM33 stabilized IN, consistent with our
previous findings, while overexpression of the wild-type protein
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cDNA, but not that of its RING mutant, accelerated its
degradation (representative blot and quantification in Fig. 5d, e
respectively). Treatment with the MG132 proteasome inhibitor
rescued the effect of wild-type TRIM33 overexpression on IN
levels. No effect of any of the treatments was observed on
simultaneously transfected EGFP protein, remarking the specifi-
city of the findings for IN.
Taken together, these results corroborate the conclusion that
TRIM33 is a novel HIV-1 IN E3 ligase that binds the IN carboxy-
terminal domain and determines its poly-ubiquitination, pending
integrity of its RING domain.
TRIM33 inhibits HIV-1 infection at the viral DNA integration
step. We wanted to understand the role of TRIM33 in HIV-1
infection. First, we assessed efficiency of single-round infection
of HeLa cells that had been depleted of TRIM33, with a VSV-G-
pseudotyped HIV-1 vector carrying the luciferase gene under the
control of the HIV-1 LTR (clone NL4-3.Luc.R-E-; Supplementary
Fig. 7a). Forty-eight hours after infection of cells in which
TRIM33 had been silenced, luciferase activity (Supplementary
Fig. 7b) and, more markedly, the levels of integrated HIV-1 DNA
(Supplementary Fig 7c) were elevated, while those of 2LTR cir-
cles markedly reduced (Supplementary Fig. 7d). In contrast,
downregulation of either Pin1 or LEDGF/p75 decreased both
the amount of integrated provirus and luciferase activity, while
2LTR formation increased only in LEDGF/p75-depleted cells.
In TRIM33-knock down cells, both early and late HIV reverse
transcripts were also slightly increased (Supplementary Fig. 7e, f
respectively), likely because of the effect of IN on the efficiency
of reverse transcription52. We verified that the downregulation of
the investigated proteins by siRNAs in these experiments was
effective (>90% decrease; representative experiment in Supple-
mentary Fig. 7g).
Supported by these findings, we wanted to assess the effect
of permanent TRIM33 knockdown on wild-type HIV-1
infection in T cells (experimental scheme in Fig. 6a). For this
purpose, we generated five VSV-G-pseudotyped lentiviral vectors,
each one expressing a different shRNA targeting TRIM33
(shRNAs #4, #5, #6, #7 and #8) and carrying a puromycin-
resistance gene to selected transduced SupT1 cell clones. Vectors
carrying shRNAs #4 and #5 were highly effective in down-
regulating the protein (representative blot in Fig. 6b; >80% of
protein reduction). A lentiviral vector carrying a control shRNA,
submitted to the same procedure, served as a control in these
experiments.
Next, we transduced SupT1 T cells expressing shRNA #4
or shRNA #5 against TRIM33 and, after 6 day-puromycin
selection, we infected these cells with wt HIV-1BRU; infection
was monitored over a course of 12 days by measuring the
amounts p24 viral protein in the cell culture supernatant.
Infection was markedly increased in cells in which TRIM33 was
knocked down (shown for anti-TRIM shRNA #4 in Fig. 6c). The
negative effect of TRIM33 was also confirmed in single-round
HIV-1NL4-3.Luc.R-E- infection of the shRNA-transduced cells, in
which luciferase activity was selectively increased in clones #4 and
#5 in which the proteins had been knocked down (experimental
scheme and results of luciferase acitivity in Supplementary
Fig. 7h, i respectively). On the contrary, overexpression of the
TRIM33 cDNA significantly decreased infection with this
molecular clone (Supplementary Fig. 7i, j for luciferase activity
and levels of TRIM33 in the transfected cells, respectively).
Our previous work had shown that an HIV-1 virus carrying the
IN(S57A) point mutation, which severely hampers IN stability, is
markedly less infectious15. Thus, we wondered whether the
knock-down of TRIM33 might revert infectivity of this molecular
clone. By analyzing T-cell infection with HIV-1BRUIN(S57A), we
indeed confirmed that this clone is markedly less infectious than
wt HIV-1BRU in control cells, however we observed that its
infectivity was completely rescued by the TRIM33 knock-down
(shown for SupT1 cells carrying anti-TRIM33 shRNA #4 in
Fig. 6c; again, superimposable results were obtained for shRNA
#5). Impairment of HIV-1BRUIN(S57A) infection and rescue by
TRIM33 downregulation was also observed by analyzing the
levels of integrated DNA by Alu-LTR at day 3 after infection
(Fig. 6d). In these experiments, TRIM33 known down resulted in
similar levels of HIV-1 integrated DNA in cells infected with wt
virus or the mutated IN clone.
We found that mutant IN(S57A) bound to TRIM33 equally
well as the wild-type protein in immunoprecipitation assays
(Supplementary Fig. 7l; however poly-ubiquitination of this
protein was significantly enhanced (representative ubiquitin blot
in Supplementary Fig. 7m and quantification in Supplementary
Fig. 7n), consistent with increased protein degradation. Transient
depletion of TRIM33 by RNAi resulted in markedly increased
stability of the IN(S57A) mutant (estimated half-life: <45 min and
>90 min in the absence and presence of TRIM33 knockdown,
respectively; Fig. 6e, f for representative images and quantifica-
tion, respectively).
Collectively, these results indicate that depletion of TRIM33
markedly augments HIV-1 infection by increasing integration of
the viral genome into the host cell DNA and is sufficient to revert
the phenotype of HIV-1BRUIN (S57A) by increasing stability of
the mutant IN protein.
We wanted to assess the role of TRIM33 in regulating
degradation of IN carried by HIV-1 during infection. We thus
infected TRIM33 KD cells, which stably express an anti-TRIM33
shRNA, with HIV-1 (25 μg of p24 per million of cells), followed
by analysis of IN levels by immunoblotting for the subsequent 5 h
(experimental scheme in Fig. 7a). Incoming HIV-1 IN degrada-
tion in the early hours after infection was markedly reduced in
cells expressing the TRIM33 shRNA (Fig. 7b). In similar
experimental conditions, we also investigated binding between
endogenous TRIM33 and virion-associated IN in control infected
cells. After 4 hour HIV-1 infection in the presence of proteasome
inhibitor, interaction between IN and TRIM was assessed by
immunoprecipitation in whole cell lysates. We found that both
TRIM33 and IN co-immunoprecipitated with the respective
partners during viral infection (Fig. 7c).
Finally, we also wanted to examine viral replication in cells
in which endogenous TRIM33 was stably knocked down and
then restored through expression of its either its wild type or
mutant cDNA. For this purpose, we generated a lentiviral vector
expressing an shRNA targeting the 3′UTR of endogenous
TRIM33 (shTRIM33(3’UTR)) and used this vector to generate
a stable SupT1 T cell line by selection for puromycin. This line
was then transduced with one of either two additional lentiviral
vectors, carrying the resistance gene for hygromycin, expressing
the coding sequences for either wild type TRIM33 or its
catalytically inactive RING mutant (TRIM33cs and RING(CA)
cs respectively); both these cDNAs were devoid of the 3′ UTR and
thus insensitive to the shRNA (scheme in Fig. 7d). After 7 days
double antibiotic selection, we verified proper expression of the
TRIM proteins in the different clones (representative western
blot and RT-PCR quantification in Fig. 7e, f and respectively)
and then infected these cells with wt HIV-1BRU; infection was
monitored over a course of 12 days by measuring the amounts
p24 viral protein production. Infection was significantly increased
in cells which stably expressed the anti-TRIM33 shRNA.
Overexpression of the TRIM33cs decreased HIV-1 infection
while this effect was blunted by expression of its catalytically
inactive mutant (Fig. 7g).
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Taken together, these results are consistent in showing that
cellular TRIM33 binds IN from infectious HIV-1 and regulates
viral replication by promoting its degradation.
Discussion
High throughput screening of a human siRNA library targeting all
known components of the ubiquitin conjugation system has
revealed that the TRIM33 RING finger E3 ligase is responsible for
HIV-1 IN degradation and thus acts an inhibitory factor for HIV-1
infection by preventing viral DNA integration. Thus, TRIM33 adds
to the group of cellular proteins that counteract different steps of
the virus life cycle, including capsid disassembly (rhesus TRIM5
proteins), prevention of reverse transcription (SAMHD-1), viral
cDNA nuclear import (MxB), release of nascent viral particles
(Tetherin/BST-2), viral RNA deamination (members of the
APOBEC3 (A3) family; reviewed in ref. 53,54) and virion infectivity
(SERINC3 and SERINC555,56). Consistent with an inhibitory role
at the pre-integration step, overexpression of TRIM33 decreased
the levels of integrated viral DNA while its knock-down had an
opposite effect. In addition, absence of TRIM33 rescued infectivity
of an HIV-1 molecular clone carrying a substitution of serine 57 to
alanine, a mutation that destabilizes integrase activity while leaving
earlier steps in the virus life cycle unaffected, including uncoating
and reverse transcription15.
In our screening for siRNAs that rescued HIV-1 IN degrada-
tion, TRIM33 was the only factor (i) that scored in the top 10
positions in the duplicate screenings, (ii) that was the most
effective in increasing IN levels when knocked down using an
siRNA pool and (iii) for which three individual siRNAs out of
four reproduced the phenotype of the siRNA pool after decon-
volution. Three other siRNA pools (against FBOX28, DTX2, and
UBE2J2) also increased IN levels significantly, but deconvolution
revealed that either the individual siRNAs composing the pools
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were not active against their respective targets or that their effect
did not increase IN levels. UBE2J2 also scored negative in the
E2 scan kit in which we analyzed the effect of all E2 enzymes.
In the cases of FBXO42, NHLRC1/Malin, and TRIM72 we
could not assess the levels of individual protein silencing since
none of the available antibodies were effective; however, the
siRNA pools against these proteins did not increase IN levels by
western blotting. No effect on IN was also the case for the RNF31,
RNF125/TRAC1, and RFPL3 siRNAs. As far as the last of these
three factors is concerned, published evidence indicates that
RFPL3 stimulates HIV-1 PIC integration activity in an in vitro
integration assay29, thus acting in an opposite manner as pre-
dicted for a destabilizing, IN-specific E3 ligase.
Past work using a yeast two hybrid system has shown that IN
can bind the von Hippel–Lindau binding protein 1 (VBP1), a
subunit of the prefolding chaperone, which bridges interaction
between IN and the cullin2 (CUL2)-based von Hippel–Lindau
(VHL) ubiquitin ligase57. In our assay conditions for IN stability,
however, siRNAs against all components of the complex (VBP1,
VHL, and CUL2) were ineffective in increasing IN levels, while
VHL scored neutral in our original screening with all E3 ligases.
Downregulation of VBP1 or VHL, however, has been reported to
markedly decrease, and not increase, HIV-1 replication, since this
interaction would be expected to occur at a step when viral cDNA
integration has already occurred and to be necessary for efficient
transcription of viral genes57. Thus VHL, in any case, would not
qualify as the E3 ligase primarily responsible for IN stability and
thus efficiency of viral cDNA integration, as instead is the case
for TRIM33.
TRIM33 (TIF1γ) belongs to the TRIM (tripartite motif) family
of proteins, which display potent antiviral activity against several
viruses39. The protein was originally discovered as its cDNA,
under low stringency conditions, cross-hybridized with a probe
corresponding to a portion TRIM24 (TIF1α), the founding
member of the TIF1 family42. In mice and humans, TRIM33 acts
as a tumor suppressor in different tissues, including hemato-
poietic compartment58, liver59 and pancreas60, and as a major
regulator of TGFβ signaling in development. In particular,
TRIM33 interacts with TGFβ receptor-activated, phosphorylated
SMAD2/3 and competes with formation of a heterodimer with
SMAD4, an essential step in TGFβ signaling61. Additionally,
TRIM33 also mediates ubiquitination of SMAD4 attenuating the
transcriptional response to TGFβ signaling, thus favoring ecto-
derm specification62,63. TRIM33 was also shown to be recruited at
sites of DNA damage in a PARP1- and ALC1- dependent man-
ner64 and to regulate cell cycle progression65,66. At the chromatin
level, TRIM33 behaves as a transcriptional co-suppressor49,67.
Our work indicates that TRIM33 suppresses HIV-1 infection
by promoting ubiquitin/proteasome-mediated degradation of IN,
thus preventing proviral formation. TRIM33 has mainly nuclear
localization, but a portion of it can also be found in the cytosol.
Thus, we speculate that it might encounter the incoming IN in
both compartments, prior to proviral formation. HIV-1 is not a
unique target for TRIM33 antiviral function, since the protein
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also limits adenoviral infection by blocking early and late gene
expression, an activity that is counteracted by the viral E4-ORF3
protein68,69.
Studies using recombinant proteins have shown that the coiled-
coil region of TRIM33 mediates heterodimerization of the protein
with TRIM2470; in addition, in mouse hepatocytes, these two
proteins are also found in complex with the third member of the
TIF1 family, TRIM2859. Of interest, our own past work has revealed
that TRIM28/KAP1 selectively binds IN post-translationally mod-
ified by acetylation and that, in complex with HDAC1, curtails viral
infection by promoting IN deacetylation71. Given these observa-
tions and considering the high similarity in domain organization
and sequence among the three TIF1 members, we wondered
whether TRIM24 or TRIM28 might also affect IN stability. We
found, however, that TRIM33 was the only one of the three proteins
to be effective. In addition, no effect of TRIM33 knock-down on the
levels of either of the two other members was detected.
TRIM33 belongs to RING-type E3 ligases, which bind both
their target proteins and ubiquitin-loaded E2-conjugating enzyme
and catalyze transfer of ubiquitin to the target17,47. Indeed, we
found that IN and TRIM33 interacted directly in vitro by pull-
down assays and in vivo by co-immunoprecipitation; integrity of
the C-terminal domain of IN and the RING domain of TRIM33
were essential for this interaction to occur. Consistent with this
information, deletion and point mutations in the TRIM33 RING
domain both impeded binding and blocked IN ubiquitination
respectively; mutations in the PHD domain were ineffective.
Thus, HIV-1 IN adds to the list of cellular proteins the stability of
which is regulated by the E3 ubiquitin ligase activity of TRIM33,
capable to induce both ubiquitination (for SMAD462 and
LDB172) and SUMOylation (for SnoN173).
In addition to their substrates, RING-type E3 ligases also
directly bind their cognate E2 conjugating enzymes. Approxi-
mately 35 of these E2 enzymes are predicted to exist, all of which
contain a catalytic (Ubc) domain with an active site cysteine
residue74. Known members of the TRIM family specifically
interact with the D and E subclasses of E2 conjugating enzymes,
except TRIM9, which interacts with UBE2G2 and TRIM32 with
UBE2V1/V275. By scanning the effect of 34 purified E2 enzymes
in the presence of TRIM33 we found that multiple E2s were able
to assist this E3 ligase in the poly-ubiquitination of IN. This
redundancy well explains why no specific E2 enzymes were
detected in our primary siRNA screening for IN stability.
The effect of TRIM33 in determining IN poly-ubiquitination and
degradation was specific for the HIV-1 enzyme. In contrast, the
Moloney MLV IN was long-lived, relatively insensitive to even high
doses of proteasome inhibitor and unaffected by TRIM33 down-
regulation. In addition, sensitivity of HIV-1 IN to TRIM33-
mediated proteasomal degradation was increased by silencing of
LEDGF/p75, Ku70, and Pin1, while no protective effect of these
factors was detected for MLV IN. LEDGF/p75 is a selective partner
of HIV-IN5,12,13, while Ku70 was shown to bind both HIV-1 IN14
and MLV IN76. For both factors, binding to HIV-1 IN was also
shown to prevent its proteasomal degradation7,14. Thus, we can
speculate that the protective effect of these factors on HIV-1 IN
stability is exerted by masking binding to TRIM33, a conclusion
that can be tested experimentally using recombinant factors.
In the case of Pin1, this enzyme isomerizes phosphorylated HIV-
1 IN and this conformational change increases IN stability15. Again,
it can be postulated that cis-trans isomerization of HIV-1 IN alters
TRIM33 recognition. Finally, of additional potential interest for
future research, our experiments also reveal that knock-down of
Pin1 increased MLV IN, opposite of HIV-1 IN, possibly hinting to a
still undefined role of this isomerase on MLV stability.
The molecular effects exerted by TRIM33 on the stability of
HIV-1 IN have significant impact on the infectivity of HIV-1
virions. Overexpression of the protein curtails HIV-1 infection,
while its silencing enhances it, as proven by both single-round
infections or standard infections with wild type virus. Of note,
our results show that TRIM33 knock-down reverts the phenotype
of an HIV-1 virus carrying the IN(S57A) point mutation, which
our past work had shown to be less infectious because its IN is
more prone to proteasomal degradation15. This finding repre-
sents a further indication of the relevance of the TRIM33 E3
ligase in the HIV-1 life cycle.
Finally, we have previously reported that HIV-1 integrates its
DNA in euchromatic regions in correspondence to the nuclear
periphery and have suggested that this peculiar localization might
be the inevitable consequence of the relatively short life of viral
IN, which would prevent effective inward diffusion of the virus77.
Based on the results shown here, we predict that TRIM33 knock
down would allow the virus to also reach inner compartments in
the nuclear interior, a hypothesis that will be tested in future
experiments.
Methods
Cells and antibodies. HeLa (ATCC, CCL-2) and HEK293T (TaKaRa Bio USA no.
632273) cell were maintained in DMEM supplemented with 10% FBS and genta-
mycin (Sigma). Jurkat and SupT1 cells (NIH Research and Reference Reagent
Program) were maintained in RPMI with 10% FBS. Primary human CD4+ T cells
were isolated by Ficoll-Percoll gradient separation78 from blood followed by pur-
ification with CD4 MicroBeads (Miltenyi Biotec). CD4+ T Cells were activated
with a cocktail of beads containing 4.5 × 105 beads coated with CD3 and CD28
antibodies (Dynabeads Human T-Activator CD3/CD28 Dynal/Invitrogen), and
plated in complete medium with IL-2 (30 U/ml, Sigma-Aldrich) for 4 days at 37 °C.
The following antibodies were used: anti-IN (SantaCruz, sc-69721, dilution
1:1000), anti-GFP (SantaCruz, sc-8334, 1:500), anti-β-catenin (SantaCruz, sc-
70509, 1:1000), anti-JNK1/2 (SantaCruz, sc-571, 1:500), anti-UBE2J2 (SantaCruz,
sc-134139, 1:500), anti-DTX2 (SantaCruz, sc-101938, 1:500), anti-Pin1 (SantaCruz,
sc-53924, 1:500), anti-Ku70 (Bethyl laboratories, 1:1000), anti-TRIM33 (Bethyl
laboratories, A301-060A, 1:1000), anti-TRIM24 (Bethyl laboratories, A300-816A,
1:1000), anti-TRIM28 (Bethyl laboratories, A300-274A, 1:1000), anti-FBXO28
(Bethyl laboratories, A302-377A, 1:1000), anti-LEDGF/p75(Bethyl laboratories,
A300-848A, 1:1000), anti-CUL2(Bethyl laboratories, A302-476A, 1:1000), anti-
VHL(Cell signaling#2738, 1:1000), anti-RNF31(Abcam, ab85294, 1:1000), anti-
RNF125(Abcam, ab74373, 1:1000), anti-TRIM33 (Cell Signaling, #13387, 1:1000),
anti-Ubiquitin (Cell Signaling, #3933, 1:1000), anti-K48 (Cell Signaling, #8081,
1:1000) and anti-K63 (Cell Signaling, #5621, 1:100), anti-GFP (Molecular Probe
Invitrogen, A6455, 1:1000), anti-RFPL3 (Life Span Biosciences, LS-B2822, 1:500),
anti-PARP1(ENZO Life Sciences, ALX-210-302-R100, 1:1000) and anti-HA
(Roche, 11867423001, 1:5000). Anti-Flag (F3165, 1:2000), anti-Flag-HRP (A8592,
1:5000), anti-Tubulin (T5168, 1:10,000) and anti-HSC70 (SAB3701436, 1:10,000)
and anti-β-actin HRP (AC-15, 1:10,000) were all purchased from Sigma. Anti-
phosphorylated IN antibodies were previously described77.
Plasmids and vectors. EGFP-IN was provided by Anna Cereseto (University of
Trento, Italy), pCS2-FlagTRIM33 and its variants were provided by Stefano Piccolo
(University of Padova, Italy), Expression vectors for GST-IN full length and GST-
IN truncated domains (N-terminus, Core and C-terminus) were previously
described15,79. pFlag-IN CO was provided by Alan Engelman (Dana-Farber Cancer
Institute, Boston, MA). pNL4-3.Luc.R-E- was a gift from Nathaniel Landau (New
York University, NY, USA). The lentiviral vector expressing the TRIM33 cDNA
was kindly provided by David A. Calderwood (Yale University School of Medicine,
New Haven, USA); other TRIM33 lentiviral vectors were purchased from Open
Biosystem (Huntsville, AL) and control pLKO.1based scramble lentiviral vector
was purchased from Addgene. Molecular viral clones pBruINwt and PBruIN
(S57A)mt were previously described15.
siRNA screening. The siRNA library corresponding to all known human genes in
the cellular ubiquitin-proteasome conjugation system (~598 target genes, siGEN-
OME SMARTpools, 4 siRNAs per gene target) was purchased from Dharmacon,
Thermo Scientific For the screening, siRNAs were transferred robotically from
stock library plates to 96-well plates (PerkinElmer) leaving 2 columns empty for the
addition of controls (buffer, non targeting siRNAs, siRNAs against UBC, Pin1, and
JNKs). SiRNAs were transfected into HeLa cells using a standard reverse trans-
fection protocol, at a final siRNA concentration of 50 nM. Briefly, the transfection
reagent (Lipofectamine RNAiMAX, Life Technologies) was diluted in OPTI-MEM
(Life Technologies) and added to the siRNAs arrayed on 96-well plates; 30 min
later, 8.0 × 103 cells were seeded per well. Twenty-four hr after siRNA transfection,
EGFP-tagged IN was transfected using a standard protocol, at a final concentration
of 100 ng reporter plasmid per well. Briefly, the transfection reagent (FugeneHD,
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Promega) was diluted in OPTI-MEM (Life Technologies), mixed with the plasmid
DNA, and added to the siRNA-transfected plates; after 48 h, cells were fixed and
processed for immunofluorescence. Screening was performed in duplicate. The
screening was performed at the ICGEB High-Throughput Screening Facility
(http://www.icgeb.org/high-throughput-screening.html).
Image acquisition and analysis. Image acquisition was performed using an
ImageXpress Micro automated high-content screening fluorescence microscope
(Molecular Devices) at a ×10 magnification; a total of 16 images were acquired per
wavelength, well and replicate (~10,000–15,000 cells per well and replicate). Image
analysis was performed using the ‘Multi-Wavelength Cell Scoring’ application
module implemented in MetaXpress software (Molecular Devices). Briefly, nuclei
were segmented based on Hoechst 33342 staining, and cells were then classified as
positive or negative depending on the total area of GFP-IN staining.
Immunoprecipitation and immunofluorescence. For immunoprecipitation, cell
pellets were lysed in lysis buffer (50m Tris HCl pH 7.5,150 mM NaCl, 1 mMEDTA,
0.5% NP40) containing protease inhibitors (Roche). Protein concentration of the
extracts was determined using the Bradford assay (BioRad). Anti-Flag M2 agarose
beads (Sigma) and anti-GFP antibodies were incubated overnight at 4 °C with cell
extracts (0.5–1 mg). Following incubation, Protein-A agarose beads (Santa Cruz)
were used to bind the immunocomplexes, according to the manufacturer's
instructions. After incubation, beads were washed 5 times with lysis buffer, and
then processed for SDS-PAGE and immunoblotting using appropriate antibodies.
For co-immunoprecipitation from HIV-1 infected cells, cells were lysed in cold
lysis buffer (35 mM Tris HCl pH 7.5, 175 mM NaCl, 0.5 mM DTT, 1.25 mM
MgCl2, and 0.05% NP-40) containing protease inhibitors. TRIM33 and IN anti-
bodies were conjugated with Dynabeads™ Protein G (Invitrogen) and 3 mg of total
protein lysates were used for immunoprecipitation according to the manufacturer’s
instructions.
In vivo ubiquitination assay. For in vivo ubiquitination, HEK293T cells were co-
transfected with EGFP-IN, wild type TRIM33 and its mutants and HA-tagged
ubiquitin plasmids by standard calcium phosphate method. After 30 h, cells were
pretreated with the proteasome inhibitor MG132 before harvesting. Whole cell
extracts were prepared in RIPA buffer - 50 mM Tris-HCl, pH 8.0, 150 mM NaCl,
1 mM EDTA, 1 mM PMSF, 0.5% NP40, protease inhibitor cocktail (Roche) - and
1.5 mg protein was immunoprecipitated with specific antibody. After immuno-
precipitation, the samples were extensively washed and resolved by SDS-PAGE
and analyzed by western blotting using appropriate antibodies.
Cellular fractionation. HeLa cells were transfected with a Flag-IN expressing
plasmid (2 µg/well) in 6-well plates. After 48 h, cells were treated with proteasome
inhibitor for 4 h. Cells were then washed with 1XPBS, trypsinized, collected into
tubes and washed with cold PBS. Cellular fractionation was performed using a
subcellular protein fractionation kit as described by the manufacturer (Thermo
Fisher). Fractionated samples were separated by SDS-PAGE and electro blotted to
a nitrocellulose membrane. IN and TRIM33 subcellular distribution and different
sub cellular markers (Tubulin and PARP1) were monitored by immunoblotting
using antibodies against IN as anti-Flag, anti-TRIM33, -Tubulin, and -PARP1.
Ubiquitin E2-conjugating enzyme screening. In vitro ubiquitin conjugation
reactions were conducted in 20 μl containing UBE1, one of 34 different recom-
binant E2 enzymes, 2 mM ATP, 400 μM ubiquitin, purified recombinant TRIM33
E3 ligase and GST-IN at 37 °C for 1 h, according to the manufacturer’s instructions
(Ubiquigent E2scan kit, Cambridge, USA). CHIP E3 ligase/UBE2D4 were used as a
positive control for the ubiquitination reaction, as it undergoes auto-ubiquitination.
After 1 h, the reactions were stopped with SDS-PAGE sample buffer and resolved
in 8% SDS-PAGE and analyzed by western blotting using anti-ubiquitin and
anti-IN antibodies.
Virus production and infection. Infectious viral stocks were produced by trans-
fecting the plasmid expressing the viral genome into HEK293T cells by standard
calcium phosphate method and collecting supernatants after 48 h. The molecular
clone for HIV-1BRU corresponds to that of HIV-1LAI. Viral production was
quantified in the supernatants for HIV-1 p24 antigen content using the Innotest
HIV antigen mAB kit (Innogenetics N.V. Gent, Belgium). Before infection, the
viral stock was treated with 40 U/ml DNAse I (Life Sciences) for 1 h at 25 °C.
HeLa/SupT1/primary CD4+ T cells (1x106) were then infected with 1 μg of p24 for
4 h in the presence of polybrene (Sigma). After infection, cells were kept in culture
at 1 × 106 cells/ml in complete medium supplemented with IL-2. At days 3, 5, 7,
and 10 post-infection, media and IL-2 were replaced and cells were kept at a
density of 1 × 106/ml. The Env- molecular clone pNL4-3.Luc.E-R-, a kind gift from
Nathaniel Landau, harbors a frameshift mutation introduced near the 5′ end of
envelope gene80 and performs a single-round infection once pseudotyped with
the Vesicular Stomatitis Virus–G (VSV-G) protein.
Lentiviral particles were produced in HEK293T cells by transfecting 20 μg
plasmid expressing shRNA, 1 μg packaging vector (pCMVdelta8.91) and 5 μg
pMD-VSG-G for pseudotyped envelope. Lentiviral particles were collected after
48–72 h post transfection and titers were quantified in the supernatants as the
amounts of HIV-1 p24 antigen using the Innotest HIV antigen mAB kit
(Innogenetics N.V. Gent, Belgium). Lentiviral transduced cells were selected in
puromycin-containing medium.
Integration assay (Alu-LTR). HIV-1 integration was examined in infected cells by
isolating genomic DNA from 1×106 cells using the DNeasy Tissue Kit (Qiagen). Alu-
LTR sequences were amplified from 100–300 ng total genomic DNA in a first round
PCR using LM667 and Alu1 primers, followed by a second round real-time PCR
using one fifth of the first amplicon as a template together with the l-specific primer
λT, the internal LTR primer LR and the probe ZXF-P81. Real-time PCR amplifications
were performed on an AbiPrism 7000 machine, using the TaqMan technology
(Applied Biosystem). Results were normalized to the amount of extracted cellular
DNA of the single-copy Lamin B2 gene, quantified by real-time PCR.
Luciferase assay. For the gene-silencing experiments, Pin1, LEDGF/p75, and
TRIM33 depleted cells were infected with pseudotyped VSV-G pNL4.3.Luc.E-R-
HIV-1 virus. Luciferase assays were performed after 48 h of infection with a
Luciferase Assay kit (Promega). To normalize luciferase activity, total protein
concentrations were determined in whole cell extracts of infected cells with the
Bradford reagent (BioRad), according to manufacturer’s protocol).
In vitro binding assays. In vitro translated S35-TRIM33 was produced using TNT-
SP6 rabbit reticulocyte lysate (Promega) and pCS2-TRIM33 as a template. Full
length GST-IN and its truncated variants (NTD, CCD, and CTD) purifications and
in vitro binding were performed using standard procedures82. To remove con-
taminant bacterial nucleic acids, recombinant proteins were pretreated with
nucleases (0.25 unit/µl Dnase I and 0.2 µg/µl RNase) for 1 h at 25 °C in 50 mM Tris
HCl, pH 8.0, 5 mM MgCl2, 2.5 mM CaCl2, 100 mM NaCl, 5% glycerol, 1 mM
DTT. Subsequently, GST fusion proteins immobilized on agarose beads were
washed and resuspended in NETN buffer (20 mM Tris HCl, pH7.5, 100 mM NaCl,
1 mM EDTA, 0.5% NP-40, 1 mM DTT, 1 mM phenylmethylsulfonylfluoride). In
vitro binding between GST-IN and GST-IN truncated variants were performed by
incubating 2 µg of recombinant with 400 cpm of in vitro translated TRIM33 in a
NETN buffer supplemented with 200 µg/ml ethidium bromide for 1 h at 4 °C on a
rotating wheel, following five washes in NETN buffer and once wash with 10 mM
Tris HCl pH 8.0/100 mM NaCl. Finally bound proteins were separated by elec-
trophoresis in an SDS 10% polyacrylamide gel, analyzed by phosphoimaging
(Cyclone) and stained with Coomassie Brilliant blue dye.
RNA extraction and real-time PCR. Total mRNA was isolated from HeLa cells
72 h after siRNA transfection using a standard Trizol RNA extraction protocol. The
RNA obtained (1 μg) was reverse-transcribed using MLV-RT (Invitrogen) with
random hexameric primers (10 μM) in a 20-μl reaction following the manu-
facturer’s instructions. Quantification of VBP1 and TRIM33 gene expressions was
performed by quantitative Real-Rime PCR using the forward and reverse primers.
Expression of the housekeeping gene GAPDH was used for normalization.
Amplifications were performed using a BIORAD CFX96 machine using GoTaq
qPCR Master Mix (Promega). The Real-Time qPCR program was programmed
with a melting curve dissociation protocol (from 60 °C to 95 °C), according to
the manufacturer’s instructions.
Primers and probes. The following oligodeoxynucletide primers and probes were
used in this study.
Alu15′-TCCCAGCTACTGGGGAGGCTGAGG-3′
LM6675′-
ATGCCACGTAAGCGAAACTCTGGCTAACTAGGGAACCCACTG-3′
LR5′-TCCACACTGACTAAAAGGGTCTGA-3′
λT5′-ATGCCACGTAAGCGAAACT-3′
ZXF-P (probe)5′-TGTGACTCTGGTAACTAGAGATCCCTCAGACCC-3′
B13 fwd5′-CCCCAGGGAGTAGGTTGTGA-3′
B13 rev5′-TGTTATTTGAGAAAAGCCCAAAGAC-3′
VBP1 fwd5′-TTGTGGCAAAGGAGAAATGGC-3′
VBP1 rev5′-CTCATTCCCAGGCTGTTTCATG-3′
TRIM33 fwd5′-AGCTTGACACCACCTCTCTC-3′
TRIM33 rev5′-CATGAGGCTTCGAATTGGGG-3′
Data availability
The authors declare that all data supporting the findings of this study are available within
the paper and its supplementary information files. Primary raw data related to the high
throughput screening results are available in Supplementary Table 1. Source data for
blottings are shown in Supplementary Fig. 8.
Received: 27 February 2018 Accepted: 23 January 2019
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08810-0 ARTICLE
NATURE COMMUNICATIONS |          (2019) 10:926 | https://doi.org/10.1038/s41467-019-08810-0 | www.nature.com/naturecommunications 13
References
1. Brown, P. O. Integration of retroviral DNA. Curr. Top. Microbiol. Immunol.
157, 19–48 (1990).
2. Nick, V. & Alan, E. Molecular mechanisms of HIV integration and therapeutic
intervention. Expert Rev. Mol. Med. 9, 1–19 (2007).
3. Mulder, L. C. & Muesing, M. A. Degradation of HIV-1 integrase by the N-end
rule pathway. J. Biol. Chem. 275, 29749–29753 (2000).
4. Tasaki, T. et al. A family of mammalian E3 ubiquitin ligases that contain
the UBR box motif and recognize N-degrons. Mol. Cell Biol. 25, 7120–7136
(2005).
5. Emiliani, S. et al. Integrase mutants defective for interaction with LEDGF/p75
are impaired in chromosome tethering and HIV-1 replication. J. Biol. Chem.
280, 25517–25523 (2005).
6. Devroe, E., Engelman, A. & Silver, P. A. Intracellular transport of human
immunodeficiency virus type 1 integrase. J. Cell Sci. 116, 4401–4408 (2003).
7. Llano, M., Delgado, S., Vanegas, M. & Poeschla, E. M. Lens epithelium-derived
growth factor/p75 prevents proteasomal degradation of HIV-1 integrase.
J. Biol. Chem. 279, 55570–55577 (2004).
8. Gerard, A., Soler, N., Segeral, E., Belshan, M. & Emiliani, S. Identification
of low molecular weight nuclear complexes containing integrase during the
early stages of HIV-1 infection. Retrovirology 10, 13 (2013).
9. Dueck, M. & Guatelli, J. Evidence against a direct antiviral activity of the
proteasome during the early steps of HIV-1 replication. Virology 361, 1–8
(2007).
10. Schwartz, O., Marechal, V., Friguet, B., Arenzana-Seisdedos, F. & Heard, J. M.
Antiviral activity of the proteasome on incoming human immunodeficiency
virus type 1. J. Virol. 72, 3845–3850 (1998).
11. Brown, P. O., Bowerman, B., Varmus, H. E. & Bishop, J. M. Retroviral
integration: structure of the initial covalent product and its precursor, and a
role for the viral IN protein. Proc. Natl Acad. Sci. USA 86, 2525–2529 (1989).
12. Maertens, G. et al. LEDGF/p75 is essential for nuclear and chromosomal
targeting of HIV-1 integrase in human cells. J. Biol. Chem. 278, 33528–33539
(2003).
13. Ciuffi, A. et al. A role for LEDGF/p75 in targeting HIV DNA integration. Nat.
Med. 11, 1287–1289 (2005).
14. Zheng, Y., Ao, Z., Wang, B., Jayappa, K. D. & Yao, X. Host protein Ku70 binds
and protects HIV-1 integrase from proteasomal degradation and is required
for HIV replication. J. Biol. Chem. 286, 17722–17735 (2011).
15. Manganaro, L. et al. Concerted action of cellular JNK and Pin1 restricts HIV-1
genome integration to activated CD4+ T lymphocytes. Nat. Med. 16, 329–333
(2010).
16. Pickart, C. M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem.
70, 503–533 (2001).
17. Deshaies, R. J. & Joazeiro, C. A. RING domain E3 ubiquitin ligases. Annu. Rev.
Biochem. 78, 399–434 (2009).
18. Schulman, B. A. & Harper, J. W. Ubiquitin-like protein activation by E1
enzymes: the apex for downstream signalling pathways. Nat. Rev. Mol. Cell
Biol. 10, 319–331 (2009).
19. Ye, Y. & Rape, M. Building ubiquitin chains: E2 enzymes at work. Nat. Rev.
Mol. Cell Biol. 10, 755–764 (2009).
20. Scheffner, M., Nuber, U. & Huibregtse, J. M. Protein ubiquitination involving
an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 373, 81–83 (1995).
21. Budhidarmo, R., Nakatani, Y. & Day, C. L. RINGs hold the key to ubiquitin
transfer. Trends Biochem. Sci. 37, 58–65 (2012).
22. Rotin, D. & Kumar, S. Physiological functions of the HECT family of ubiquitin
ligases. Nat. Rev. Mol. Cell Biol. 10, 398–409 (2009).
23. Huibregtse, J. M., Scheffner, M., Beaudenon, S. & Howley, P. M. A family of
proteins structurally and functionally related to the E6-AP ubiquitin-protein
ligase. Proc. Natl Acad. Sci. USA 92, 2563–2567 (1995).
24. Lam, S. Y. et al. The human ubiquitin conjugating enzyme UBE2J2 (Ubc6) is a
substrate for proteasomal degradation. Biochem. Biophys. Res. Commun. 451,
361–366 (2014).
25. Lenk, U. et al. A role for mammalian Ubc6 homologues in ER-associated
protein degradation. J. Cell Sci. 115, 3007–3014 (2002).
26. Kipreos, E. T. & Pagano, M. The F-box protein family. Genome Biol. 1,
REVIEWS3002 (2000).
27. Kratz, A. S. et al. Fbxo28 promotes mitotic progression and regulates
topoisomerase IIalpha-dependent DNA decatenation. Cell Cycle 15,
3419–3431 (2016).
28. Cepeda, D. et al. CDK-mediated activation of the SCF(FBXO) (28) ubiquitin
ligase promotes MYC-driven transcription and tumourigenesis and predicts
poor survival in breast cancer. EMBO Mol. Med. 5, 1067–1086 (2013).
29. Tan, B. H. et al. Identification of RFPL3 protein as a novel E3 ubiquitin ligase
modulating the integration activity of human immunodeficiency virus, type 1
preintegration complex using a microtiter plate-based assay. J. Biol. Chem.
289, 26368–26382 (2014).
30. Kirisako, T. et al. A ubiquitin ligase complex assembles linear polyubiquitin
chains. EMBO J. 25, 4877–4887 (2006).
31. Yamamoto, N. et al. Role of Deltex-1 as a transcriptional regulator
downstream of the Notch receptor. J. Biol. Chem. 276, 45031–45040 (2001).
32. Endo, Y., Osumi, N. & Wakamatsu, Y. Deltex/Dtx mediates NOTCH signaling
in regulation of Bmp4 expression in cranial neural crest formation during
avian development. Dev. Growth Differ. 45, 241–248 (2003).
33. Gentry, M. S., Worby, C. A. & Dixon, J. E. Insights into Lafora disease: malin
is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of
laforin. Proc. Natl Acad. Sci. USA 102, 8501–8506 (2005).
34. Traore, M. et al. Novel mutation in the NHLRC1 gene in a Malian family
with a severe phenotype of Lafora disease. Neurogenetics 10, 319–323
(2009).
35. Kecmanovic, M. et al. Lafora disease: severe phenotype associated with
homozygous deletion of the NHLRC1 gene. J. Neurol. Sci. 325, 170–173
(2013).
36. Giannini, A. L., Gao, Y. & Bijlmakers, M. J. T-cell regulator RNF125/TRAC-1
belongs to a novel family of ubiquitin ligases with zinc fingers and a ubiquitin-
binding domain. Biochem. J. 410, 101–111 (2008).
37. Shoji-Kawata, S. et al. The RING finger ubiquitin ligase RNF125/TRAC-1
down-modulates HIV-1 replication in primary human peripheral blood
mononuclear cells. Virology 368, 191–204 (2007).
38. Jia, X. et al. The ubiquitin ligase RNF125 targets innate immune adaptor
protein TRIM14 for ubiquitination and degradation. J. Immunol. 198,
4652–4658 (2017).
39. Nisole, S., Stoye, J. P. & Saib, A. TRIM family proteins: retroviral restriction
and antiviral defence. Nat. Rev. Microbiol. 3, 799–808 (2005).
40. Ozato, K., Dong-Mi, S., Tsung-Hsien, C. & Herbert, C. M. TRIM family
proteins and their emerging roles in innate immunity. Nat. Rev. Immunol. 8,
849–860 (2008).
41. Zhang, Y., Wu, H. K., Lv, F. & Xiao, R. P. MG53: biological function and
potential as a therapeutic target. Mol. Pharmacol. 92, 211–218 (2017).
42. Venturini, L. et al. TIF1gamma, a novel member of the transcriptional
intermediary factor 1 family. Oncogene 18, 1209–1217 (1999).
43. Hatakeyama, S. TRIM proteins and cancer. Nat. Rev. Cancer 11, 792–804
(2011).
44. Aberle, H., Bauer, A., Stappert, J., Kispert, A. & Kemler, R. beta-catenin is a
target for the ubiquitin-proteasome pathway. EMBO J. 16, 3797–3804 (1997).
45. Herquel, B., Ouararhni, K. & Davidson, I. The TIF1alpha-related TRIM
cofactors couple chromatin modifications to transcriptional regulation,
signaling and tumor suppression. Transcription 2, 231–236 (2011).
46. Peng, H. et al. Reconstitution of the KRAB-KAP-1 repressor complex: a model
system for defining the molecular anatomy of RING-B box-coiled-coil
domain-mediated protein-protein interactions. J. Mol. Biol. 295, 1139–1162
(2000).
47. Berndsen, C. E. & Wolberger, C. New insights into ubiquitin E3 ligase
mechanism. Nat. Struct. Mol. Biol. 21, 301–307 (2014).
48. Tanaka, S. et al. Trim33 mediates the proinflammatory function of Th17 cells.
J. Exp. Med. 215, 1853–1868 (2018).
49. Agricola, E., Randall, R. A., Gaarenstroom, T., Dupont, S. & Hill, C. S.
Recruitment of TIF1gamma to chromatin via its PHD finger-bromodomain
activates its ubiquitin ligase and transcriptional repressor activities. Mol. Cell
43, 85–96 (2011).
50. Kitano, K., Kim, S.-Y. & Hakoshima, T. Structural basis for DNA strand
separation by the unconventional winged-helix domain of RecQ helicase
WRN. Structure 18, 177–187 (2010).
51. Lorick, K. L. et al. RING fingers mediate ubiquitin-conjugating enzyme (E2)-
dependent ubiquitination. Proc. Natl Acad. Sci. USA 96, 11364–11369 (1999).
52. Wu, X. et al. Human immunodeficiency virus type 1 integrase protein
promotes reverse transcription through specific interactions with the
nucleoprotein reverse transcription complex. J. Virol. 73, 2126–2135 (1999).
53. Jia, X., Zhao, Q. & Xiong, Y. HIV suppression by host restriction factors and
viral immune evasion. Curr. Opin. Struct. Biol. 31, 106–114 (2015).
54. Simon, V., Bloch, N. & Landau, N. R. Intrinsic host restrictions to HIV-1 and
mechanisms of viral escape. Nat. Immunol. 16, 546–553 (2015).
55. Rosa, A. et al. HIV-1 Nef promotes infection by excluding SERINC5 from
virion incorporation. Nature 526, 212–217 (2015).
56. Usami, Y., Wu, Y. & Gottlinger, H. G. SERINC3 and SERINC5 restrict HIV-1
infectivity and are counteracted by Nef. Nature 526, 218–223 (2015).
57. Mousnier, A. et al. von Hippel Lindau binding protein 1-mediated
degradation of integrase affects HIV-1 gene expression at a postintegration
step. Proc. Natl Acad. Sci. USA 104, 13615–13620 (2007).
58. Aucagne, R. et al. Transcription intermediary factor 1gamma is a tumor
suppressor in mouse and human chronic myelomonocytic leukemia. J. Clin.
Invest. 121, 2361–2370 (2011).
59. Herquel, B. et al. Transcription cofactors TRIM24, TRIM28, and TRIM33
associate to form regulatory complexes that suppress murine hepatocellular
carcinoma. Proc. Natl Acad. Sci. USA 108, 8212–8217 (2011).
60. Vincent, D. F. et al. Inactivation of TIF1gamma cooperates with Kras to
induce cystic tumors of the pancreas. PLoS Genet. 5, e1000575 (2009).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08810-0
14 NATURE COMMUNICATIONS |          (2019) 10:926 | https://doi.org/10.1038/s41467-019-08810-0 | www.nature.com/naturecommunications
61. He, W. et al. Hematopoiesis controlled by distinct TIF1gamma and Smad4
branches of the TGFbeta pathway. Cell 125, 929–941 (2006).
62. Dupont, S. et al. Germ-layer specification and control of cell growth by
Ectodermin, a Smad4 ubiquitin ligase. Cell 121, 87–99 (2005).
63. Morsut, L. et al. Negative control of Smad activity by ectodermin/Tif1gamma
patterns the mammalian embryo. Development 137, 2571–2578 (2010).
64. Kulkarni, A. et al. Tripartite Motif-containing 33 (TRIM33) protein functions
in the poly(ADP-ribose) polymerase (PARP)-dependent DNA damage
response through interaction with Amplified in Liver Cancer 1 (ALC1)
protein. J. Biol. Chem. 288, 32357–32369 (2013).
65. Sedgwick, G. G. et al. Transcriptional intermediary factor 1gamma binds to
the anaphase-promoting complex/cyclosome and promotes mitosis. Oncogene
32, 4622–4633 (2013).
66. Pommier, R. M. et al. TIF1gamma suppresses tumor progression by regulating
mitotic checkpoints and chromosomal stability. Cancer Res. 75, 4335–4350
(2015).
67. Xi, Q. et al. A poised chromatin platform for TGF-beta access to master
regulators. Cell 147, 1511–1524 (2011).
68. Forrester, N. A. et al. Adenovirus E4orf3 targets transcriptional intermediary
factor 1gamma for proteasome-dependent degradation during infection.
J. Virol. 86, 3167–3179 (2012).
69. Sohn, S. Y. & Hearing, P. The adenovirus E4-ORF3 protein functions as a
SUMO E3 ligase for TIF-1gamma sumoylation and poly-SUMO chain
elongation. Proc. Natl Acad. Sci. USA 113, 6725–6730 (2016).
70. Peng, H., Feldman, I. & Rauscher, F. J. 3rd Hetero-oligomerization among the
TIF family of RBCC/TRIM domain-containing nuclear cofactors: a potential
mechanism for regulating the switch between coactivation and corepression.
J. Mol. Biol. 320, 629–644 (2002).
71. Allouch, A. et al. The TRIM family protein KAP1 inhibits HIV-1 integration.
Cell Host Microbe 9, 484–495 (2011).
72. Howard, P. W., Ransom, D. G. & Maurer, R. A. Transcription intermediary
factor 1gamma decreases protein expression of the transcriptional cofactor,
LIM-domain-binding 1. Biochem. Biophys. Res. Commun. 396, 674–678
(2010).
73. Ikeuchi, Y. et al. TIF1gamma protein regulates epithelial-mesenchymal
transition by operating as a small ubiquitin-like modifier (SUMO) E3 ligase
for the transcriptional regulator SnoN1. J. Biol. Chem. 289, 25067–25078
(2014).
74. van Wijk, S. J. et al. A comprehensive framework of E2-RING E3 interactions
of the human ubiquitin-proteasome system. Mol. Syst. Biol. 5, 295 (2009).
75. Napolitano, L. M. & Meroni, G. TRIM family: pleiotropy and diversification
through homomultimer and heteromultimer formation. IUBMB Life 64,
64–71 (2012).
76. Studamire, B. & Goff, S. P. Interactions of host proteins with the murine
leukemia virus integrase. Viruses 2, 1110–1145 (2010).
77. Marini, B. et al. Nuclear architecture dictates HIV-1 integration site selection.
Nature 521, 227–231 (2015).
78. Repnik, U., Knezevic, M. & Jeras, M. Simple and cost-effective isolation of
monocytes from buffy coats. J. Immunol. Methods 278, 283–292 (2003).
79. Cereseto, A. et al. Acetylation of HIV-1 integrase by p300 regulates viral
integration. EMBO J. 24, 3070–3081 (2005).
80. Connor, R. I., Chen, B. K., Choe, S. & Landau, N. R. Vpr is required for
efficient replication of human immunodeficiency virus type-1 in mononuclear
phagocytes. Virology 206, 935–944 (1995).
81. Tan, W., Dong, Z., Wilkinson, T. A., Barbas, C. F. 3rd & Chow, S. A. Human
immunodeficiency virus type 1 incorporated with fusion proteins consisting
of integrase and the designed polydactyl zinc finger protein E2C can bias
integration of viral DNA into a predetermined chromosomal region in human
cells. J. Virol. 80, 1939–1948 (2006).
82. Marzio, G., Tyagi, M., Gutierrez, M. I. & Giacca, M. HIV-1 Tat transactivator
recruits p300 and CREB-binding protein histone acetyltransferases to the viral
promoter. Proc. Natl Acad. Sci. USA 95, 13519–13524 (1998).
Acknowledgements
We are very grateful to A. Cereseto, N. Landau, S. Piccolo, A. Engelman,
D.A. Calderwood and L. Mulder for the kind gifts of reagents. This work was
supported by the Intramural Funding Programme of the ICGEB to the Molecular
Medicine Laboratory in Trieste, Italy.
Author contributions
H.A., A.N., C.C., M.D.V. and B.M. performed the experiments and analyzed the data.
M.M. and L.B. performed the original HTS screening. G.M. and M.L. analyzed the data.
H.A., M.L., and M.G. conceived and designed the experiments. H.A. and M.G. wrote
the manuscript
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
019-08810-0.
Competing interests: The authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Journal peer review information: Nature Communications thanks the anonymous
reviewers for their contribution to the peer review of this work.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08810-0 ARTICLE
NATURE COMMUNICATIONS |          (2019) 10:926 | https://doi.org/10.1038/s41467-019-08810-0 | www.nature.com/naturecommunications 15
